268 results on '"Miglioresi, L"'
Search Results
52. P.17.12 SCREENING FOR HCV INFECTION IN A COHORT OF IMMIGRANTS WITH A RAPID ORAL FLUID TEST
53. The impact of IL-28B polymorphism and diabetes on SVR after antiviral therapy (AT) for post-liver transplant (LT) HCV recurrence
54. Long term NUC treatment in hepatitis B virus HBeAg negative genotype D patients and risk for hepatocellular carcinoma: Evidence from the CLEO cohort study
55. Recipient and donor gender match predicts the outcome of antiviral therapy for recurrent hepatitis C
56. Treatment of genotype-1 hepatitis C recurrence after liver transplant improves survival in both sustained responders and relapsers
57. Treatment of recurrent genotype 4 hepatitis C after liver transplantation: early virological response is predictive of sustained virological response. An AISF RECOLT-C group study
58. The persistence of HCV replication is associated with an increased mortality rate in HCV recurrent transplant patients: Results from the AISF-RECOLT-C group
59. Acute and chronic rejection during interferon therapy in HCV recurrent transplant patients: Results from the AISF-RECOLT-C group
60. THU-082 - Accuracy of the Radiological Diagnosis of Hepatocellular Carcinoma outside the Periodic Surveillance with Ultrasound
61. Svr To Antiviral Therapy Is Highly Protective Against Liver-related Death In Patients With Hcv Recurrence On the Graft After Liver Transplantation (lt)
62. Treatment of Genotype 1 Hcv Infection Recurrence After Liver Transplantation: the Achievement of Svr Improves Long-term Survival. An Italian Multicentric Study
63. Saggio su: 'LaMORTE A VENEZIA' di Thomas Mann
64. De Novo Malignancies Following Liver Transplantation: Results From a Multicentric Study in Central and Southern Italy, 1990–2008
65. 484 IMPACT OF LIVER FIBROSIS IN DEVELOPMENT OF HEPATOCELLULAR CARCINOMA IN GENOTYPE 1 CHRONIC HEPATITIS C PATIENTS TREATED WITH ANTIVIRAL THERAPY: LONG TERM FOLLOW UP STUDY
66. 139 AN UNFAVORABLE INTERACTION BETWEEN DONOR AGE AND LATENT RECIPIENT CYTOMEGALOVIRUS (CMV) INFECTION AFTER LIVER TRANSPLANTATION (LT): INSIGHTS FROM THE LIVER MATCH STUDY
67. P.18.2 LONG-TERM MAINTENANCE OF SVR IN DIFFICULT-TO-TREAT HCV GENOTYPES IN LIVER TRANSPLANT RECIPIENTS WITH HCV RECURRENCE
68. T-45 Features of patients with extrahepatic metastasis of hepatocellular carcinoma and clinical impact on survival: experience of a single Italian center
69. P.04.4 SVR TO ANTIVIRAL TREATMENT FOR POST-OLT RECURRENT HCV HEPATITIS CAN BE IMPROVED BY THE USE OF GROWTH FACTORS
70. P.03.6 IS THE PRIMARY IMMUNOSUPPRESSIVE DRUG (CYCLOSPORIN A OR TACROLIMUS) PLAYING A ROLE ON THE RESPONSE TO ANTIVIRAL TREATMENT FOR POST-TRANSPLANT HCV RECURRENCE?
71. P.04.9 THE PRESENCE OF DIABETES REDUCES SVR AFTER ANTIVIRAL THERAPY FOR POST-TRANSPLANT HCV RECURRENCE
72. F-46 Graft survival is worse in HCV positive females transplanted with male donor grafts
73. 563 ACUTE AND CHRONIC REJECTION DURING INTERFERON THERAPY IN HCV RECURRENT TRANSPLANT PATIENTS: RESULTS FORM THE AISF-RECOLT-C GROUP
74. 523 PROTRACTED ANTIVIRAL TREATMENT BEYOND CONVENTIONAL TIME LIMITS IMPROVES SURVIVAL IN NON-RESPONDERS TO INTERFERON+RIBAVIRIN ADMINISTERED FOR HCV RECURRENCE AFTER LIVER TRANSPLANTATION
75. P.1.54: TREATMENT OF THE “UNCOMMON” HCV GENOTYPE 4 INFECTION RECURRENCE AFTER LIVER TRANSPLANTATION. AN “AISF RECOLT-C” STUDY
76. P.1.3: ACUTE AND CHRONIC REJECTION DURING INTERFERON THERAPY IN HCV RECURRENT LIVER TRANSPLANT PATIENTS: RESULTS FROM THE AISF-RECOLT-C GROUP
77. 578 IS THE PRIMARY IMMUNOSUPPRESSIVE DRUG (CYCLOSPORIN A OR TACROLIMUS) PLAYING A ROLE ON THE RESPONSE TO ANTIVIRAL TREATMENT FOR POST-TRANSPLANT HCV RECURRENCE?
78. 561 BEST MATCHING FOR HCV GENOTYPE 1 LIVER TRANSPLANT RECIPIENTS IS PREDICTED BY HCV1-STAR. A STUDY FROM AISF RECOLT-C DATABASE
79. P.1.7: A SVR TO POST-LT ANTIVIRAL TREATMENT IMPROVES LONG-TERM SURVIVAL IN PATIENTS WITH GENOTYPE 1 HCV RECURRENCE: AN “AISF RECOLT-C” GROUP STUDY
80. P.1.2: THE PERSISTENCE OF HCV REPLICATION IS ASSOCIATED WITH AN INCREASED MORTALITY RATE IN HCV RECURRENT TRANSPLANT PATIENTS: RESULTS FROM THE AISF-RECOLT-C GROUP
81. PC.1.4: THE BEST MATCHING FOR HCV GENOTYPE 1 LIVER TRANSPLANT RECIPIENTS IS PREDICTED BY HCV1-STAR. A STUDY FROM AISF RECOLT-C DATABASE
82. 579 THE PRESENCE OF DIABETES REDUCES SVR AFTER ANTIVIRAL THERAPY FOR POST-TRANSPLANT HCV RECURRENCE
83. 427 TREATMENT OF HEPATITIS C RECURRENCE AFTER LIVER TRANSPLANTATION: GENDER ISSUE ON THERAPY OUTCOME
84. 464 TREATMENT OF THE “UNCOMMON” HCV GENOTYPE 4 INFECTION RECURRENCE AFTER LIVER TRANSPLANTATION. AN ITALIAN MULTICENTRIC EXPERIENCE
85. P.1.5: POOR ADHERENCE TO PEGYLATED INTERFERON AND RIBAVIRIN IS A MAJOR CONCERN IN THE TREATMENT OF RECURRENT HEPATITIS C AFTER LIVER TRANSPLANTATION: EVIDENCE FROM THE AISF RECOLT-C STUDY GROUP
86. 532 POOR ADHERENCE TO PEGYLATED-INTERFERON AND RIBAVIRIN IS A MAJOR CONCERN IN THE TREATMENT OF RECURRENT HEPATITIS C AFTER LIVER TRANSPLANTATION: EVIDENCE FROM THE RECOLT-C GROUP
87. T-44 Impact of antiviral therapy on fibrosis progression due to HCV recurrence after liver transplantation: Results from the AISF RECOLT-C study group
88. OC-7 A SVR to post-LT antiviral treatment improves long-term survival in patients with genotype 1 HCV recurrence: An “AISF RECOLT-C” Group Study
89. F-39 Is the primary immunosuppressive drug playing a role on the response to antiviral treatment for post-transplant HCV recurrence?
90. T-43 Treatment of the “uncommon” HCV genotype 4 infection recurrence after liver transplantation. Data from AISF RECOLT-C group
91. T-24 Donor-related characteristics as predictors of sustained virologic response to antiviral therapy in recurrent hepatitis C after liver transplantation
92. F-48 HCV relapses occur within 3 months after treatment in liver transplanted patients receiving pegylated IFN and ribavirin
93. F-31 The persistence of HCV replication is associated with an increased mortality rate in HCV recurrent transplant patients: Results from the AISF-RECOLT-C group
94. T-23 Poor adherence to pegylated interferon and ribavirin is a major concern in the treatment of hepatitis C after liver transplantation: Evidence from the AISF RECOLT-C study group
95. F-10 Acute and chronic rejection during interferon therapy in HCV recurrent transplant patients: Results from the AISF-RECOLT-C group
96. OC-24 The best matching for HCV genotype 1 liver transplant recipients is predicted by HCV1-STAR. A study from “AISF RECOLT-C” database
97. DE NOVO TUMORS AFTER LIVER TRANSPLANTATION: RESULTS FROM A MULTICENTRIC STUDY, ITALY 1990–2008.
98. T.N.49 FIBROSIS PROGRESSION IN NON RESPONDERS TO ANTIVIRAL TREATMENT (AT) FOR HCV RECURRENCE FOLLOWING LIVER TRANSPLANTATION (LT)
99. The controversial role of lamivudine prophylaxis in occult HBV carriers treated with chemo-immune therapy
100. Consensus interferon versus interferon-α 2b plus ribavirin in patients with relapsing HCV infection
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.